Lineagen (www.lineagen.com) is a provider of diagnostic and healthcare services focused on complex diseases for which individuals genetic profiles contribute strongly to their susceptibility. Lineagen is committed to improving outcomes for those affected by autism and other complex diseases, for which effective early diagnosis and intervention can have a significant positive impact. The Company's comprehensive genetic testing and support/counseling service are initially designed to enable early evaluation of children at risk for disorders of childhood development, including autism spectrum disorders (ASDs). Founded in 2002, Lineagen's commercial strategy represents the culmination of significant proprietary research into genetic causes and diagnostic pathways of key complex diseases, including autism, MS and COPD. One of the company's core research competitive advantages is its access through the University of Utah to the Utah Population Database, an unmatched biomarker discovery research platform that has been used to help the University identify more disease-related genes than any other institution in the world.
Current Team (3)Update
Funding Rounds (5) - $43MUpdate
Oldest investment firms
Early stage venture capital firm
Signal Peak is a venture capital firm with more than $450 million of committed capital under...
The University Venture Fund (UVF) is the largest student-managed venture capital fund ($18.2M) in...
Hatteras Funds provides an array of unique alternative investment solutions. A boutique...
Mesa Verde Venture Partners, L.P. is a life sciences venture capital fund founded in San Diego in...
Archipel Capital was added to CrunchBase in 2013
Utah-based Seed Fund
423 Wakara Way
Salt Lake City, UT 84108